This Article Full Text Full Text (PDF) CME: Take the course for this article: Course on Antifibrinolytic Therapy for Surgery in Patients with Congenital Heart Disease Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Eaton, M. P. Search for Related Content PubMed PubMed Citation Articles by Eaton, M. P. Related Collections Cardiovascular Heart Coagulation Pediatrics Pharmacology

---

CARDIOVASCULAR ANESTHESIOLOGY

Antifibrinolytic Therapy in Surgery for Congenital Heart Disease

From the Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York.

Address correspondence to Michael P. Eaton, MD, 601 Elmwood Avenue, Box 604, Rochester, NY. Address e-mail to Michael_Eaton{at}URMC.rochester.edu.

Abstract

The efficacy of the serine protease inhibitor, aprotinin, and the lysine analogs, -aminocaproic acid and tranexamic acid, in reducing bleeding and transfusion in adults undergoing cardiac surgery is well established. Although children undergoing cardiac surgery are clearly at high risk for bleeding and transfusion, the risks and benefits of this therapy for the pediatric population are less well understood. There is a reasonable body of literature examining antifibrinolytic therapy in congenital heart surgery, but the large variability in patients studied, procedures, methods, and dosing schemes makes a quantitative analysis of this literature impractical. A qualitative review of this literature reveals significant support for the efficacy of all three drugs for decreasing bleeding and transfusion in congenital heart surgery, likely with more benefit in certain populations. Limited data suggest that there is no difference in efficacy among the three drugs, although aprotinin may have unique antiinflammatory effects that are of benefit in pediatric patients. There is not enough evidence to draw any conclusions about the safety of these drugs in children, although it appears that the risk of anaphylaxis with aprotinin in children may be less than in adults. Dosing schemes used for these drugs have been variable and not always based on sound pharmacologic principles, despite available pharmacokinetic and pharmacodynamic data. Further research should be directed toward establishing safety, evaluating the relative efficacy of the two classes of drugs, proving benefit in specific patient groups, and better defining effective dosing schemes.

This article has been cited by other articles:

				A. Manrique, E. H. Jooste, B. A. Kuch, S. E. Lichtenstein, V. Morell, R. Munoz, D. Ellis, and P. J. Davis The Association of Renal Dysfunction and the Use of Aprotinin in Patients Undergoing Congenital Cardiac Surgery Requiring Cardiopulmonary Bypass Anesth. Analg., July 1, 2009; 109(1): 45 - 52. [Abstract] [Full Text] [PDF]